Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 8/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 8/20 | 0.43 |
| ▸ | IL23R | Q5VWK5 | 2/20 | 0.42 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.42 |
| ▸ | MC4R | P32245 | 4/20 | 0.39 |
| ▸ | MC5R | P33032 | 2/20 | 0.39 |
| ▸ | MC3R | P41968 | 2/20 | 0.39 |
| ▸ | MC1R | Q01726 | 2/20 | 0.39 |
| ▸ | F2R | P25116 | 2/20 | 0.38 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.38 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.38 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13144377 | 0.92 | OPRM1 (0.48) | OPRM1OPRK1IL23RC5AR1F2R | |
| SCHEMBL13145229 | 0.89 | OPRM1 (0.47) | OPRM1OPRK1IL23RC5AR1F2R | |
| SCHEMBL13144378 | 0.89 | IL23R (0.53) | IL23RC5AR1MC4RMC5RMC3R | |
| SCHEMBL13144883 | 0.86 | OPRM1 (0.51) | OPRM1OPRK1NMUR2NMUR1 | |
| SCHEMBL13144630 | 0.85 | C5AR1 (0.50) | OPRM1OPRK1IL23RC5AR1MC4R | |
| SCHEMBL13478161 | 0.85 | OPRM1 (0.48) | OPRM1OPRK1MC4RNMUR2NMUR1 | |
| SCHEMBL13145221 | 0.84 | OPRM1 (0.48) | OPRM1OPRK1NMUR2NMUR1 | |
| SCHEMBL13144373 | 0.84 | CXCL8 (0.49) | IL23RC5AR1CXCL8 | |
| SCHEMBL13144366 | 0.83 | C5AR1 (0.51) | IL23RC5AR1MC4RMC5RMC3R | |
| SCHEMBL13144545 | 0.83 | MC4R (0.55) | IL23RMC4RMC5RMC3RMC1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267639-A1 | TREATMENT OF OSTEOARTHRITIS | PROMICS PTY LIMITED (AU) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267639-A1 | TREATMENT OF OSTEOARTHRITIS | C5AR2, C5AR1, C3AR1 | OPRM1 254/4885OPRK1 267/4885IL23R 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.